Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status - PubMed (original) (raw)
Multicenter Study
. 2006 Apr 1;107(7):2889-94.
doi: 10.1182/blood-2005-06-2227. Epub 2005 Nov 29.
Alexander Kröber, Fiona Murray, Ulf Thunberg, Gerard Tobin, Andreas Bühler, Dirk Kienle, Emilia Albesiano, Rossana Maffei, Lan-Phuong Dao-Ung, James Wiley, Juhani Vilpo, Anna Laurell, Mats Merup, Göran Roos, Karin Karlsson, Nicholas Chiorazzi, Roberto Marasca, Hartmut Döhner, Stephan Stilgenbauer, Richard Rosenquist
Affiliations
- PMID: 16317103
- DOI: 10.1182/blood-2005-06-2227
Free article
Multicenter Study
Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status
Mia Thorsélius et al. Blood. 2006.
Free article
Abstract
We recently reported that Swedish VH3-21-using chronic lymphocytic leukemia (CLL) patients showed restricted immunoglobulin gene features and poor prognosis despite VH mutation status. To investigate this further, we analyzed the VH and VL gene rearrangements in 90 VH3-21+ patients from Sweden, Germany, Italy, United States, Finland, and Australia and correlated these data with survival and other prognostic markers. Sixty-three percent exhibited mutated VH genes and 37% unmutated VH genes. Fifty (56%) patients displayed a short and homologous heavy-chain CDR3, many of these with the amino acid motif DANGMDV. Also, a highly biased Vlambda2-14 use was evident in 72% of patients with a restricted light-chain CDR3, QVWDS(S/G)SDHPWV. Combined restricted heavy- and light-chain CDR3s were found in patients from all included countries. Although VH3-21+ CLLs have a remarkably predominant lambda expression, analyses of kappa deleting element indicated a conserved light-chain rearrangement order. The overall survival was poor in the VH3-21+ cohort (median survival, 88 months), with no significant difference in relation to mutation status or CDR3 homology. High ZAP-70 and CD38 expression was found in both mutated and unmutated VH3-21+ cases as well as a slight increase of 11q-aberrations. In summary, highly restricted B-cell receptors and worse outcome characterize VH3-21+ CLLs independent of geographic origin and mutation status.
Similar articles
- Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope.
Tobin G, Thunberg U, Johnson A, Eriksson I, Söderberg O, Karlsson K, Merup M, Juliusson G, Vilpo J, Enblad G, Sundström C, Roos G, Rosenquist R. Tobin G, et al. Blood. 2003 Jun 15;101(12):4952-7. doi: 10.1182/blood-2002-11-3485. Epub 2003 Feb 13. Blood. 2003. PMID: 12586612 - The immunoglobulin genes and chronic lymphocytic leukemia (CLL).
Tobin G. Tobin G. Ups J Med Sci. 2005;110(2):97-113. doi: 10.3109/2000-1967-075. Ups J Med Sci. 2005. PMID: 16075892 Review. - Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemia.
Capello D, Guarini A, Berra E, Mauro FR, Rossi D, Ghia E, Cerri M, Logan J, Foà R, Gaidano G. Capello D, et al. Leukemia. 2004 Dec;18(12):1941-7. doi: 10.1038/sj.leu.2403537. Leukemia. 2004. PMID: 15483675 - Pattern and distribution of immunoglobulin VH gene usage in a cohort of B-CLL patients from a Northeastern region of Italy.
Donisi PM, Di Lorenzo N, Riccardi M, Paparella A, Sarpellon C, Zupo S, Bertoldero G, Minotto C, Stracca-Pansa V. Donisi PM, et al. Diagn Mol Pathol. 2006 Dec;15(4):206-15. doi: 10.1097/01.pdm.0000213469.85301.d6. Diagn Mol Pathol. 2006. PMID: 17122648 - What do somatic hypermutation and class switch recombination teach us about chronic lymphocytic leukaemia pathogenesis?
Oppezzo P, Dighiero G. Oppezzo P, et al. Curr Top Microbiol Immunol. 2005;294:71-89. doi: 10.1007/3-540-29933-5_5. Curr Top Microbiol Immunol. 2005. PMID: 16323428 Review.
Cited by
- Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs.
Urso A, Martino EA, Cuneo A, Gentile M, Rigolin GM. Urso A, et al. Cancers (Basel). 2024 Jul 31;16(15):2732. doi: 10.3390/cancers16152732. Cancers (Basel). 2024. PMID: 39123460 Free PMC article. Review. - Association of Cytogenetics Aberrations and IGHV Mutations with Outcome in Chronic Lymphocytic Leukemia Patients in a Real-World Clinical Setting.
Muñoz-Novas C, González-Gascón-Y-Marín I, Figueroa I, Sánchez-Paz L, Pérez-Carretero C, Quijada-Álamo M, Rodríguez-Vicente AE, Infante MS, Foncillas MÁ, Landete E, Churruca J, Marín K, Ramos V, Sánchez Salto A, Hernández-Rivas JÁ. Muñoz-Novas C, et al. Glob Med Genet. 2024 Feb 12;11(1):59-68. doi: 10.1055/s-0044-1779668. eCollection 2024 Jan. Glob Med Genet. 2024. PMID: 38348157 Free PMC article. - Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia.
Bagnara D, Mazzarello AN, Ghiotto F, Colombo M, Cutrona G, Fais F, Ferrarini M. Bagnara D, et al. Int J Mol Sci. 2022 Nov 17;23(22):14249. doi: 10.3390/ijms232214249. Int J Mol Sci. 2022. PMID: 36430731 Free PMC article. Review. - Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia.
Kaufman M, Yan XJ, Li W, Ghia EM, Langerak AW, Rassenti LZ, Belessi C, Kay NE, Davi F, Byrd JC, Pospisilova S, Brown JR, Catherwood M, Davis Z, Oscier D, Montillo M, Trentin L, Rosenquist R, Ghia P, Barrientos JC, Kolitz JE, Allen SL, Rai KR, Stamatopoulos K, Kipps TJ, Neuberg D, Chiorazzi N. Kaufman M, et al. Front Oncol. 2022 Jul 12;12:897280. doi: 10.3389/fonc.2022.897280. eCollection 2022. Front Oncol. 2022. PMID: 35903706 Free PMC article. - Immune receptor CDR3 chemical features that preserve sequence information are highly efficient in reflecting survival distinctions: A pan-cancer analysis.
Mcbreairty BE, Chobrutskiy BI, Chobrutskiy A, Gozlan EC, Diaz MJ, Blanck G. Mcbreairty BE, et al. Biomed Rep. 2022 Jun 9;17(2):68. doi: 10.3892/br.2022.1551. eCollection 2022 Aug. Biomed Rep. 2022. PMID: 35815190 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials